ArticleNature communications2018
Integrated genetic and epigenetic analysis of myxofibrosarcoma.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges.JCO precision oncology · 2022Pooled it
- Historical contributions and future horizons of Japanese orthopaedic oncology: from surgical innovation to nationwide collaborations.International orthopaedics · 2026Article
- Evolution of Recurrent Myxofibrosarcoma of the Thoracic Wall at Single-Cell Resolution: A Case Report.International journal of molecular sciences · 2026Article
- Cutaneous soft tissue tumors in the 5th edition of the World Health Organization classification of skin tumors: key updates and new entities.Journal of pathology and translational medicine · 2026Article
- Early recurrence of left atrial myxofibrosarcoma: A case report of a clinical and histopathologic challenge.Journal of cardiothoracic surgery · 2026Article
- Integrated diagnostic evaluation of multiple malignant neoplasms viaOncology letters · 2026Article
- Recurrent primary intracranial myxofibrosarcoma: a case report and review of the literature.Frontiers in oncology · 2026Article
- A Ten-Step Surgical Approach to Radical Excision of a Primary Ischiorectal Fossa Tumor With IGAP V-Y Flap Reconstruction-A Case Report of a Rare Myxofibrosarcoma.Clinical case reports · 2025Article
- Article
- The role of molecular pathology in soft tissue tumor diagnosis: what the radiologist needs to know.Skeletal radiology · 2025Review
- Unveiling the myxofibrosarcoma tumor microenvironment: implications for immunotherapy.Frontiers in immunology · 2025Review
- Establishment and characterization of two novel patient-derived cell lines from myxofibrosarcoma: NCC-MFS7-C1 and NCC-MFS8-C1.Human cell · 2024Article
- Genetic Screen in a Preclinical Model of Sarcoma Development Defines Drivers and Therapeutic Vulnerabilities.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- The Role of Methylation Analysis in Distinguishing Cellular Myxoma from Low-Grade Myxofibrosarcoma.International journal of molecular sciences · 2024Article
- Functional Classification of Fusion Proteins in Sarcoma.Cancers · 2024Review
- Review
- Biology and Management of High-Grade Myxofibrosarcoma: State of the Art and Future Perspectives.Diagnostics (Basel, Switzerland) · 2023Review
- Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic Overview.JCO precision oncology · 2023Article
- GLUT-1 expression is helpful to distinguish myxofibrosarcoma from nodular fasciitis.Histology and histopathology · 2023Article
- PAK1 overexpression promotes myxofibrosarcoma angiogenesis through STAT5B-mediatedInternational journal of biological sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myxofibrosarcoma (MFS) is a common adult soft tissue sarcoma characterized by an infiltrative growth pattern and a high local recurrence rate. Here we report the genetic and epigenetic landscape of MFS based on the results of whole-exome sequencing (N = 41), RNA sequencing (N = 29), and methylation analysis (N = 41), using 41 MFSs as a discovery set, and subsequent targeted sequencing of 140 genes in the entire cohort of 99 MFSs and 17 MFSs' data from TCGA. Fourteen driver genes are identified, including potentially actionable therapeutic targets seen in 37% of cases. There are frequent alterations in p53 signaling (51%) and cell cycle checkpoint genes (43%). Other conceivably actionable driver genes including ATRX, JAK1, NF1, NTRK1, and novel oncogenic BRAF fusion gene are identified. Methylation patterns cluster into three subtypes associated with unique combinations of driver mutations, clinical outcomes, and immune cell compositions. Our results provide a valuable genomic resource to enable the design of precision medicine for MFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.